SEBI confirms market ban on Nirman Agri Genetics in IPO fund case

The Enforcement Action

The Securities and Exchange Board of India (SEBI) has confirmed its restraint on Nirman Agri Genetics Limited (NAGL) and its promoter and managing director, Mr Pranav Kailas Bagal, in a matter concerning the alleged diversion of the company's initial public offering (IPO) proceeds. The confirmatory order, numbered WTM/KV/CFID/CFID-SEC2/32656/2026-27 and dated 10 August 2026, was passed by Whole Time Member Kamlesh Chandra Varshney in exercise of powers under Sections 11(1), 11(4) and 11B(1) of the SEBI Act, 1992.

The order confirms ad-interim directions first issued through an interim order dated 14 October 2025. Per that interim order, an examination into the utilisation of the funds NAGL raised through its IPO revealed what SEBI described as "a systematic diversion and siphoning of approximately 93%" of the IPO proceeds. NAGL, listed on the exchanges and named by PAN AAHCN1021C, stands restrained from accessing the securities market until further orders. Mr Bagal (PAN EHJPB8209L) remains barred from buying, selling or dealing in the NAGL scrip. The company was also directed to halt its proposed bonus issue, stock split and change of name.

Responding at a video-conference hearing on 16 July 2026, the noticees' representatives submitted that some of the funds alleged to have been diverted had been received back in the company's account, and asked that the curbs on corporate actions be vacated given the firm's profitable financials. SEBI records that no written submissions were filed despite repeated extensions.

How the Scheme Worked

According to the order, NAGL was incorporated in August 2020, has its registered office in Nashik, Maharashtra, and is engaged in producing and marketing agricultural hybrid seeds, crop-protection products, pesticides and bio-organics. The regulator's examination centred on what happened to the money the company collected from public investors when it came to market.

Per SEBI's interim findings, roughly 93 per cent of the IPO proceeds were moved out of the company shortly after listing. The interim order alleges the funds were "routed through conflicting vendor profiles, non-existent entities, and shell layers", ultimately benefiting the promoter group and connected persons. In the accounts, SEBI observes, large sums were booked as unverified "advances for purchases", so that, in the regulator's words, the company's public financials "do not present a true and fair picture" of its operations.

The procedural chronology set out in the order is as follows. The interim order of 14 October 2025 gave the noticees 21 days to file replies and to seek a hearing. Their authorised representatives inspected the documents after seeking multiple extensions but filed no written objections. A personal hearing set for 13 May 2026 was deferred at the noticees' request; their representatives eventually appeared by video conference on 16 July 2026 and made oral submissions, then sought a further two weeks to file written submissions with supporting documents. Those submissions never arrived.

Weighing the oral defence, SEBI held that any claim of money being repatriated was unsupported by evidence, and that "bringing back part of their diversion does not erase the initial act" of routing public money through layered or suspect entities. The regulator was also wary of the pending corporate actions. As noted in the interim order, a stock split, bonus issue and name change "may artificially increase liquidity and market float" and, taken together, "appear designed to induce retail investor participation" - creating, in SEBI's assessment, a risk of further offloading of shares onto unsuspecting investors while the matter is under investigation.

The Law Invoked

The confirmatory order is grounded in the SEBI Act, 1992. Section 11(1) sets out SEBI's overarching duty to protect the interests of investors and to regulate the securities market. Section 11(4) empowers the regulator to pass interim directions, including restraining a person or company from accessing or dealing in securities while an examination is under way. Section 11B(1) allows SEBI to issue such directions as it deems fit in the interest of investors or of the market, and Section 19 permits the delegation of these powers to the Whole Time Member who signed the order.

Read together, these provisions are the statutory basis for a preventive, protective restraint rather than a final penalty. The order itself is careful on this point: it confirms the ad-interim measures but records that "the observations made in the present Order are tentative in nature, pending detailed investigation." No monetary penalty, disgorgement figure or debarment period is fixed at this stage; those would follow only a final order, if the detailed investigation bears out the prima facie case of alleged fund diversion and fraud.

What Happens Next

The directions took effect immediately and remain in force until further orders. SEBI has said its detailed investigation will proceed "without being influenced by any of the directions passed or any observation made" in either the interim or the confirmatory order, and that "appropriate action shall be taken in accordance with law" once it concludes. That later action could range from vacating the restraint to a final order carrying disgorgement, monetary penalties or a longer market ban - or none of these, depending on what the investigation establishes.

Any person aggrieved by a SEBI order may appeal to the Securities Appellate Tribunal (SAT) under Section 15T of the SEBI Act, generally within 45 days, and thereafter to the Supreme Court on a question of law. At this stage the regulator's conclusions are expressly prima facie. They are allegations that remain to be tested through SEBI's own detailed inquiry and the appellate process; nothing in the order records a final finding of guilt.

What It Means

For ordinary investors, the order is a reminder that what a newly-listed company does with its IPO money is both disclosed and enforceable. Every mainboard and SME IPO must state the objects of the issue in its offer document, and larger issues appoint a monitoring agency that reports on how the proceeds are actually deployed. Reading the "objects of the issue" and the monitoring-agency reports filed with the exchanges is the simplest way to check whether a company is spending investor money as promised.

The order also flags a documented pattern worth watching in small, freshly-listed stocks: a rapid sequence of bonus issues, stock splits and name changes. SEBI's concern here is not that such actions are inherently wrong, but that they can be used to manufacture liquidity and draw in retail buyers. A useful discipline is to treat aggressive corporate actions in a thinly-traded newly-listed company as a prompt for more scrutiny, not less. Investors can verify a listed company's filings and read enforcement orders directly on the SEBI website, and can confirm the registration of any broker or adviser through SEBI's public search facilities before committing money.

FAQ

Does this mean the people named are guilty?

No. SEBI's findings at this stage are expressly prima facie and "tentative in nature, pending detailed investigation". A confirmatory order preserves interim restraints; it is not a final adjudication of guilt. The noticees are entitled to due process, to a full investigation and to appeal, and remain presumed innocent of the alleged violations unless and until they are established through that process.

What exactly did SEBI order?

SEBI confirmed that Nirman Agri Genetics Limited remains barred from accessing the securities market until further orders, that its proposed bonus issue, stock split and name change stay on hold, and that its promoter-MD, Mr Pranav Kailas Bagal, cannot deal in the company's shares. The order flows from an interim order dated 14 October 2025 alleging diversion of about 93% of the IPO proceeds.

Can the order be appealed?

Yes. Any party aggrieved by a SEBI order can appeal to the Securities Appellate Tribunal under Section 15T of the SEBI Act, ordinarily within 45 days of receiving it, and can pursue a further appeal to the Supreme Court on a question of law. The confirmatory restraint also remains open to modification by SEBI itself as its investigation progresses.

What does this mean for existing NAGL shareholders?

The restraint bars the company from raising fresh capital and stops the promoter from dealing in the scrip; it does not, by its terms, freeze existing public shareholders' own holdings. Shareholders should follow the company's exchange disclosures and any further SEBI orders closely, since the outcome of the detailed investigation will shape the stock's regulatory status.

Where can I read the official order?

The confirmatory order dated 10 August 2026 is published in the enforcement section of the SEBI website, sebi.gov.in, under orders of the Whole Time Member. It sets out the reference number, the noticees, the interim directions being confirmed and the reasoning in full, and is the authoritative source for every figure and date cited in this report.

This report is based on the official SEBI confirmatory order dated 10 August 2026 in the matter of Nirman Agri Genetics Limited, read with the order document itself published on sebi.gov.in.